Indirect recognition of donor HLA-DR peptides in organ allograft rejection
- PMID: 8787678
- PMCID: PMC507537
- DOI: 10.1172/JCI118898
Indirect recognition of donor HLA-DR peptides in organ allograft rejection
Abstract
To determine whether indirect allorecognition is involved in heart allograft rejection T cells obtained from peripheral blood and graft biopsy tissues were expanded in the presence of IL-2 and tested in limiting dilution analysis (LDA) for reactivity to synthetic peptides corresponding to the hypervariable regions of the mismatched HLA-DR antigen(s) of the donor. Serial studies of 32 patients showed that T cell reactivity to donor allopeptides was strongly associated with episodes of acute rejection. The frequency of allopeptide reactive T cells was 10-50-fold higher in the graft than in the periphery indicating that T cells activated via the indirect allorecognition pathway participate actively in acute allograft rejection. In recipients carrying a graft differing by two HLA-DR alleles the response appeared to target only one of the mismatched antigens of the donor. Indirect allorecognition was restricted by a single HLA-DR antigen of the host and directed against one immunodominant peptide of donor HLA-DR protein. However, intermolecular spreading was demonstrated in patients with multiple rejection episodes by showing that they develop allopeptide reactivity against the second HLA-DR antigen. These data imply that early treatment to suppress T cell responses through the indirect pathway of allorecognition, such as tolerance induction to the dominant donor determinant, may be required to prevent amplification and perpetuation of the rejection process.
Similar articles
-
Mechanism of liver allograft rejection: the indirect recognition pathway.Hum Immunol. 1997 Mar;53(1):57-63. doi: 10.1016/S0198-8859(97)00029-3. Hum Immunol. 1997. PMID: 9127148
-
New strategies for early diagnosis of heart allograft rejection.Transplantation. 1997 Sep 27;64(6):842-7. doi: 10.1097/00007890-199709270-00009. Transplantation. 1997. PMID: 9326408
-
Indirect allorecognition of major histocompatibility complex allopeptides in human renal transplant recipients with chronic graft dysfunction.Transplantation. 1997 Sep 27;64(6):795-800. doi: 10.1097/00007890-199709270-00001. Transplantation. 1997. PMID: 9326400
-
New approaches to specific immunomodulation in transplantation.Int Rev Immunol. 1996;13(3):161-72. doi: 10.3109/08830189609061745. Int Rev Immunol. 1996. PMID: 8782739 Review.
-
Intramolecular and intermolecular spreading during the course of organ allograft rejection.Immunol Rev. 1998 Aug;164:241-6. doi: 10.1111/j.1600-065x.1998.tb01224.x. Immunol Rev. 1998. PMID: 9795780 Review.
Cited by
-
Activation and Regulation of Indirect Alloresponses in Transplanted Patients With Donor Specific Antibodies and Chronic Rejection.Transpl Int. 2024 Aug 20;37:13196. doi: 10.3389/ti.2024.13196. eCollection 2024. Transpl Int. 2024. PMID: 39228658 Free PMC article. Review.
-
CD4 T cell-mediated cardiac allograft rejection requires donor but not host MHC class II.J Clin Invest. 2000 Oct;106(8):1003-10. doi: 10.1172/JCI10467. J Clin Invest. 2000. PMID: 11032860 Free PMC article.
-
Essential concept of transplant immunology for clinical practice.World J Transplant. 2013 Dec 24;3(4):113-8. doi: 10.5500/wjt.v3.i4.113. World J Transplant. 2013. PMID: 24392315 Free PMC article. Review.
-
Integrative Analyses of Circulating Small RNAs and Kidney Graft Transcriptome in Transplant Glomerulopathy.Int J Mol Sci. 2021 Jun 9;22(12):6218. doi: 10.3390/ijms22126218. Int J Mol Sci. 2021. PMID: 34207555 Free PMC article. Clinical Trial.
-
Genetic or pharmaceutical blockade of phosphoinositide 3-kinase p110δ prevents chronic rejection of heart allografts.PLoS One. 2012;7(3):e32892. doi: 10.1371/journal.pone.0032892. Epub 2012 Mar 30. PLoS One. 2012. PMID: 22479345 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials